March 22, 2018
First Japanese company joins CARB-X partnership in the fight against drug resistant bacteria
CARB-X is partnering with Shionogi of Osaka, Japan, to support the development of a novel β-lactam antibiotic with potent activity…
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
March 20, 2018
Hikma launches Ritonavir Tablets USP
Hikma Pharmaceuticals’s wholly owned US subsidiary West-Ward Pharmaceuticals, has launched Ritonavir Tablets USP, 100 mg, the first AB-rated generic to…
March 2, 2018
BMS welcomes new Board member
Bristol-Myers Squibb’s Board of Directors has elected José Baselga, M.D., Ph.D., to the Board, effective March 1, 2018. Dr. Baselga will…
February 28, 2018
Novo Nordisk files for regulatory approval in the US and the EU for treatment of haemophilia A
Novo Nordisk has submitted a Biologics License Applications (BLA) to the US Food and Drug Administration (FDA) and a Marketing…
February 28, 2018
FDA rejects Celgene’s NDA for multiple sclerosis treatment
Celgene Corporation (NASDAQ:CELG) has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug…
February 27, 2018
Lillys breast cancer drug gets additional FDA approval
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s (NYSE: LLY) Verzenio (abemaciclib) in combination with an aromatase…
October 3, 2017
FDA accepts sNDA filing for Allergan’s pneumonia drug
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Allergan’s Avycaz (ceftazidime and avibactam) for priority review.
September 29, 2017
Eli Lilly in leadership chances
Eli Lilly has made certain leadership changes, promoting several experienced Lilly leaders to executive roles, effective in 2018.
September 29, 2017
FDA OK’s Eli Lilly’s breast cancer drug
The U.S. Food and Drug Administration has approved Eli Lilly’s Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy).
September 28, 2017
Novartis and UC Berkeley collaborate to tackle ‘undruggable’ disease targets
Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered “undruggable.”